CN114514238A - 埃立克体疫苗和免疫原性组合物 - Google Patents

埃立克体疫苗和免疫原性组合物 Download PDF

Info

Publication number
CN114514238A
CN114514238A CN202080064004.XA CN202080064004A CN114514238A CN 114514238 A CN114514238 A CN 114514238A CN 202080064004 A CN202080064004 A CN 202080064004A CN 114514238 A CN114514238 A CN 114514238A
Authority
CN
China
Prior art keywords
seq
immunogenic composition
trp140
trp36
adjuvant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080064004.XA
Other languages
English (en)
Chinese (zh)
Inventor
杰雷·W·麦克布赖德
保罗·J·多米诺夫斯基
苏曼·马汉
贾森·J·米勒希普
邓肯·M·姆旺吉
沙拉特·拉伊
沙伦·M·瓦佩尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Development Foundation
Zoetis Services LLC
Original Assignee
Research Development Foundation
Zoetis Services LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Development Foundation, Zoetis Services LLC filed Critical Research Development Foundation
Publication of CN114514238A publication Critical patent/CN114514238A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1246—Rickettsiales (O)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0233—Rickettsiales, e.g. Anaplasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/29—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Richettsiales (O)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CN202080064004.XA 2019-07-12 2020-07-13 埃立克体疫苗和免疫原性组合物 Pending CN114514238A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962873843P 2019-07-12 2019-07-12
US62/873,843 2019-07-12
US201962879762P 2019-07-29 2019-07-29
US62/879,762 2019-07-29
US202063049476P 2020-07-08 2020-07-08
US63/049,476 2020-07-08
PCT/US2020/041779 WO2021011456A1 (en) 2019-07-12 2020-07-13 Ehrlichia vaccines and immunogenic compositions

Publications (1)

Publication Number Publication Date
CN114514238A true CN114514238A (zh) 2022-05-17

Family

ID=71948757

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080064004.XA Pending CN114514238A (zh) 2019-07-12 2020-07-13 埃立克体疫苗和免疫原性组合物

Country Status (11)

Country Link
US (1) US12624093B2 (enExample)
EP (1) EP3996741A1 (enExample)
JP (1) JP2022540197A (enExample)
CN (1) CN114514238A (enExample)
AU (1) AU2020314625A1 (enExample)
BR (1) BR112022000347A2 (enExample)
CA (1) CA3146842A1 (enExample)
CL (1) CL2022000086A1 (enExample)
MX (1) MX2022000525A (enExample)
PH (1) PH12022550081A1 (enExample)
WO (1) WO2021011456A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025118050A1 (pt) * 2023-12-04 2025-06-12 Laboratório Bio-Vet Ltda Antígeno vacinal quimérico com ação tríplice contra erliquiose, anaplasmose e babesiose canina, vetor de expressão, célula recombinante, composição vacinal, kit de diagnóstico, método de tratamento e uso de proteína quimérica

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000012688A1 (en) * 1998-08-27 2000-03-09 Research Development Foundation Ehrlichia canis 120-kda immunodominant antigenic protein and gene
WO2004042037A1 (en) * 2002-11-04 2004-05-21 Research Development Foundation P153 and p156 antigens for the immunodiagnosis of canine and human ehrlichioses and uses thereof
WO2005087803A1 (en) * 2004-03-11 2005-09-22 Wyeth A canine vaccine for protection against ehrlichiosis
US20060234322A1 (en) * 2005-04-04 2006-10-19 Idexx Laboratories, Inc. Ehrlichia canis DIVA (differentiate infected from vaccinated animals)
WO2006138509A2 (en) * 2005-06-16 2006-12-28 Research Development Foundation Immunoreactive protein orthologs of ehrlichia canis and e. chaffeensis
WO2008000068A1 (en) * 2006-06-27 2008-01-03 Wellington Laboratories Inc. Method for preparing 2-iodo triterpenoid compounds
WO2008043000A2 (en) * 2006-10-04 2008-04-10 Idexx Laboratories Inc Ehrlicia canis diva (differentiate infected from vaccinated animals)
WO2008112007A1 (en) * 2006-08-31 2008-09-18 Research Development Foundation Immunoreactive glycoprotein gp19 of ehrlichia canis
WO2009156960A2 (en) * 2008-06-27 2009-12-30 Pfizer Inc. Novel adjuvant compositions
WO2010126993A1 (en) * 2009-04-28 2010-11-04 Research Development Foundation Immunoreactive ehrlichia p120/p140 epitopes and uses thereof
WO2011148356A1 (en) * 2010-05-28 2011-12-01 Coley Pharmaceutical Group, Inc. Vaccines comprising cholesterol and cpg as sole adjuvant - carrier molecules
EP2433646A1 (en) * 2010-09-22 2012-03-28 Intervet International BV Vaccine against Ehrlichia canis and associated methods
WO2013181086A1 (en) * 2012-05-31 2013-12-05 Zoetis Llc Vaccination with canine respiratory coronavirus for protection against b. bronchiseptica infections
CN109675029A (zh) * 2013-09-19 2019-04-26 硕腾服务有限责任公司 油基佐剂
CN112703197A (zh) * 2018-07-27 2021-04-23 研究发展基金会 嵌合免疫原性多肽

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2555413C (en) 2004-02-25 2013-12-17 Research Development Foundation An immunoreactive 38-kda ferric binding protein of ehrlichia canis and uses thereof
US7910593B2 (en) 2004-04-09 2011-03-22 Chugai Seiyaku Kabushiki Kaisha Water-soluble prodrugs
EP1790656A1 (en) 2005-11-25 2007-05-30 Nanokem S.A. Solution-phase synthesis of leuprolide
CL2008001806A1 (es) 2007-06-20 2008-09-05 Wyeth Corp Composicion de vacuna en emulsion agua en aceite que comprende un antigeno y un adyuvante en la fase acuosa; y metodo de elaboracion.
WO2009102509A2 (en) 2008-01-10 2009-08-20 Research Development Foundation Vaccines and diagnostics for the ehrlichioses
SI3542819T1 (sl) 2013-05-14 2021-11-30 Zoetis Services Llc Sestave novih cepiv, ki vsebujejo imunostimulatorne oligonukleotide
MX2020011887A (es) 2018-05-07 2021-03-29 Res Found Dev Polipéptidos inmunorreactivos.

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000012688A1 (en) * 1998-08-27 2000-03-09 Research Development Foundation Ehrlichia canis 120-kda immunodominant antigenic protein and gene
WO2004042037A1 (en) * 2002-11-04 2004-05-21 Research Development Foundation P153 and p156 antigens for the immunodiagnosis of canine and human ehrlichioses and uses thereof
WO2005087803A1 (en) * 2004-03-11 2005-09-22 Wyeth A canine vaccine for protection against ehrlichiosis
US20060234322A1 (en) * 2005-04-04 2006-10-19 Idexx Laboratories, Inc. Ehrlichia canis DIVA (differentiate infected from vaccinated animals)
WO2006138509A2 (en) * 2005-06-16 2006-12-28 Research Development Foundation Immunoreactive protein orthologs of ehrlichia canis and e. chaffeensis
WO2008000068A1 (en) * 2006-06-27 2008-01-03 Wellington Laboratories Inc. Method for preparing 2-iodo triterpenoid compounds
WO2008112007A1 (en) * 2006-08-31 2008-09-18 Research Development Foundation Immunoreactive glycoprotein gp19 of ehrlichia canis
WO2008043000A2 (en) * 2006-10-04 2008-04-10 Idexx Laboratories Inc Ehrlicia canis diva (differentiate infected from vaccinated animals)
WO2009156960A2 (en) * 2008-06-27 2009-12-30 Pfizer Inc. Novel adjuvant compositions
WO2010126993A1 (en) * 2009-04-28 2010-11-04 Research Development Foundation Immunoreactive ehrlichia p120/p140 epitopes and uses thereof
WO2011148356A1 (en) * 2010-05-28 2011-12-01 Coley Pharmaceutical Group, Inc. Vaccines comprising cholesterol and cpg as sole adjuvant - carrier molecules
EP2433646A1 (en) * 2010-09-22 2012-03-28 Intervet International BV Vaccine against Ehrlichia canis and associated methods
WO2013181086A1 (en) * 2012-05-31 2013-12-05 Zoetis Llc Vaccination with canine respiratory coronavirus for protection against b. bronchiseptica infections
CN109675029A (zh) * 2013-09-19 2019-04-26 硕腾服务有限责任公司 油基佐剂
CN112703197A (zh) * 2018-07-27 2021-04-23 研究发展基金会 嵌合免疫原性多肽

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TIAN LUO等: "Major Species-Specific Antibody Epitopes of the Ehrlichia chaffeensis p120 and E. canis p140 Orthologs in Surface-Exposed Tandem Repeat Regions", 《CLINICAL AND VACCINE IMMUNOLOGY》, vol. 16, no. 7, XP009122339, DOI: 10.1128/CVI.00048-09 *

Also Published As

Publication number Publication date
BR112022000347A2 (pt) 2022-04-12
CL2022000086A1 (es) 2022-09-30
JP2022540197A (ja) 2022-09-14
AU2020314625A1 (en) 2022-02-03
EP3996741A1 (en) 2022-05-18
WO2021011456A1 (en) 2021-01-21
MX2022000525A (es) 2022-04-20
CA3146842A1 (en) 2021-01-21
PH12022550081A1 (en) 2023-04-12
US20220356231A1 (en) 2022-11-10
US12624093B2 (en) 2026-05-12

Similar Documents

Publication Publication Date Title
US12195501B2 (en) Mutant fragments of OspA and methods and uses relating thereto
KR100517028B1 (ko) 경피 면역용 조성물
KR20130124525A (ko) 미코박테리움 항원성 조성물
CN101522215A (zh) 抗衣原体感染疫苗
JP6505084B2 (ja) 免疫刺激性オリゴヌクレオチドを含む新規のワクチン組成物
JP2016521754A (ja) クロストリジウム・ディフィシル（ｃ．ｄｉｆｆｉｃｉｌｅ）に対して免疫する組成物及び方法
JP2026082987A (ja) クロストリディオイデス（クロストリジウム）・ディフィシル（ｃｌｏｓｔｒｉｄｉｏｉｄｅｓ（ｃｌｏｓｔｒｉｄｉｕｍ）ｄｉｆｆｉｃｉｌｅ）に対する免疫応答を誘発するための免疫原性組成物および方法
US12624093B2 (en) Ehrlichia vaccines and immunogenic compositions
US7538083B2 (en) Compositions and methods for the potentiation of immune responses against target antigens
RU2824881C2 (ru) Вакцины против ehrlichia и иммуногенные композиции
JP5676452B2 (ja) ワクチンアジュバント
JP5901084B2 (ja) ペプチドアジュバント
KR20070117551A (ko) 점막 백신의 전달용 펩티드
JP2001151698A (ja) インフルエンザワクチン
JP2022540197A5 (enExample)
WO2023240278A2 (en) Uses of glycolipids as a vaccine adjuvant and methods thereof
WO2025257712A1 (en) Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile
JP2013510188A (ja) 黄色ブドウ球菌に由来する菌血症関連抗原
WO2015004604A1 (en) Immunogenic tp0751 fragments
EA046886B1 (ru) МУТАНТНЫЕ ФРАГМЕНТЫ OspA И СВЯЗАННЫЕ С НИМИ СПОСОБЫ И ПРИМЕНЕНИЕ

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20220517